MKULQ — Molekule Income Statement
0.000.00%
Last trade - 00:00- $0.01m
- $30.91m
- $0.23m
Annual income statement for Molekule, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0.617 | 0.227 |
| Cost of Revenue | ||||
| Gross Profit | — | — | 0.278 | 0.115 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 0.153 | 3.32 | 8.86 | 6.9 |
| Operating Profit | -0.153 | -3.32 | -8.24 | -6.67 |
| Net Income Before Taxes | -0.153 | -3.32 | -8.24 | -6.67 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.153 | -3.32 | -7.92 | -6.17 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -0.153 | -3.32 | -7.92 | -6.17 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.153 | -3.32 | -7.92 | -6.17 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.013 | -0.292 | -0.742 | -0.416 |